Furthermore, low dose, but dose dense (“metronomic”), administration of paclitaxel and cisplatin in a subcutaneous HM-1 ovarian cancer model resulted in CD8+ T-cell dependent control of tumor growth that was superior to that observed at the maximum tolerated dose (104). Here, CD8A is linked to ovarian cancer.